Search results for "PPAR"

showing 10 items of 1686 documents

European Respiratory Society statement on sleep apnoea, sleepiness and driving risk

2021

Obstructive sleep apnoea (OSA) is highly prevalent and is a recognised risk factor for motor vehicle accidents (MVA). Effective treatment with continuous positive airway pressure has been associated with a normalisation of this increased accident risk. Thus, many jurisdictions have introduced regulations restricting the ability of OSA patients from driving until effectively treated. However, uncertainty prevails regarding the relative importance of OSA severity determined by the apnoea–hypopnoea frequency per hour and the degree of sleepiness in determining accident risk. Furthermore, the identification of subjects at risk of OSA and/or accident risk remains elusive. The introduction of off…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAutomobile DrivingSleepinessmedia_common.quotation_subjectmedicine.medical_treatmentPoison controlSettore MED/10 - Malattie Dell'Apparato RespiratorioSleep ApnoeaSuicide preventionOccupational safety and healthDriving Simulators03 medical and health sciences0302 clinical medicineRisk FactorsEpidemiologyInjury preventionSleep Apnoea Driving Accident Risk Sleepiness Screening Driving Simulators Treatment RegulationsmedicineHumansContinuous positive airway pressureIntensive care medicineRegulationsmedia_commonSleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryAccidents TrafficHuman factors and ergonomicsnervous system diseasesrespiratory tract diseasesTreatment030228 respiratory systemAccident RiskScreeningHuman medicinebusiness030217 neurology & neurosurgeryDrivingVigilance (psychology)
researchProduct

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

2015

Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveSocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Anti-asthmatic AgentMedication AdherencePulmonary DiseasePulmonary Disease Chronic ObstructiveSuspensionsAdministration InhalationmedicineCOPDHumansPharmacology (medical)Anti-Asthmatic AgentsMetered Dose InhalersRespiratory systemParticle SizeIntensive care medicineAsthmaAdherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)COPDInhalationbusiness.industryMedicine (all)InhalerNebulizers and VaporizersBiochemistry (medical)Adherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)InhalerDry Powder InhalersAirway obstructionmedicine.diseaseAsthmaSolutionsInhalationAdherenceAdministrationAdherence; Asthma; COPD; InhalerbusinessPulmonary pharmacologytherapeutics
researchProduct

Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities

2007

Considerable evidence is available in support of an independent association between obstructive sleep apnoea syndrome (OSAS) and cardiovascular disease, which is particularly strong for systemic arterial hypertension and growing for ischaemic heart disease, stroke, heart failure, atrial fibrillation and cardiac sudden death. The pathogenesis of cardiovascular disease in OSAS is not completely understood but likely to be multifactorial, involving a diverse range of mechanisms including sympathetic nervous system overactivity, selective activation of inflammatory molecular pathways, endothelial dysfunction, abnormal coagulation and metabolic dysregulation, the latter particularly involving in…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioCardiovascular disease intermittent hypoxia mechanisms obstructive sleep apnoeaMetabolic DiseasesRisk FactorsDiabetes mellitusInternal medicinemedicineHumansmedia_common.cataloged_instanceEuropean unionIntensive care medicineStrokemedia_commonSleep Apnea ObstructiveMechanism (biology)business.industryResearchSleep apneaAtrial fibrillationmedicine.diseaseEndocrinologyCardiovascular DiseasesHeart failurebusinessEuropean Respiratory Journal
researchProduct

Obstructive sleep apnea and comorbidities: a dangerous liaison

2018

Obstructive sleep apnea (OSA) is a highly prevalent disease, and is traditionally associated with increased cardiovascular risk. The role of comorbidities in OSA patients has emerged recently, and new conditions significantly associated with OSA are increasingly reported. A high comorbidity burden worsens prognosis, but some data suggest that CPAP might be protective especially in patients with comorbidities. Aim of this narrative review is to provide an update on recent studies, with special attention to cardiovascular and cerebrovascular comorbidities, the metabolic syndrome and type 2 diabetes, asthma, COPD and cancer. Better phenotypic characterization of OSA patients, including comorbi…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyDiseaseType 2 diabetesReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences0302 clinical medicinecardiovascular diseaseDiabetes mellitusmedicinecancerCOPDMortalityIntensive care medicineAsthmalcsh:RC705-779COPDdiabetesbusiness.industrylcsh:Diseases of the respiratory systemasthmamedicine.diseaseComorbiditynervous system diseasesrespiratory tract diseasesObstructive sleep apnea030228 respiratory systemdiabeteprognosisMetabolic syndromebusiness030217 neurology & neurosurgeryMultidisciplinary Respiratory Medicine
researchProduct

Treatment of heart failure with preserved ejection fraction.

2018

Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to high mortality and the frequent need for hospitalization, with a consequent heavy burden on healthcare resources. For an appropriate treatment of heart failure with preserved ejection fraction (HFpEF), there are no specific drugs effective for this condition. Those indicated in HF with reduced EF (HFrEF) are of more benefit in that form of HF, according to the guidelines of the European Society of Cardiology of 2016: ACE-inhibitors, beta-blockers, anti-aldosterones are all indicated with a class of recommendation/level of evidence IA; therapy with loop diuretics is indicated in the case of clin…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEjection fractionSettore MED/09 - Medicina Internalcsh:Medicineheart failuretherapeutic strategies.Hospitalization rateInternal medicineMedicineAerobic exerciseguidelinesEjection fraction; comorbidity; guidelines; heart failure; therapeutic strategies.Ejection fractionbusiness.industryHigh mortalitylcsh:REvidence-based medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolarecomorbidityHeart failureCardiologyCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessguidelineMonaldi archives for chest disease = Archivio Monaldi per le malattie del torace
researchProduct

Mild obstructive sleep apnea increases hypertension risk, challenging traditional severity classification

2020

STUDY OBJECTIVES: The association of mild obstructive sleep apnea (OSA) with important clinical outcomes remains unclear. We aimed to investigate the association between mild OSA and systemic arterial hypertension (SAH) in the European Sleep Apnea Database cohort. METHODS: In a multicenter sample of 4,732 participants, we analyzed the risk of mild OSA (subclassified into 2 groups: mild(AHI 5-<11/h) (apnea-hypopnea index [AHI], 5 to <11 events/h) and mild(AHI 11-<15/h) (AHI, ≥11 to <15 events/h) compared with nonapneic snorers for prevalent SAH after adjustment for relevant confounding factors including sex, age, smoking, obesity, daytime sleepiness, dyslipidemia, chronic obstructive pulmona…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEuropean Sleep Apnea Database Mild obstructive sleep apnea Systemic arterial hypertensionPolysomnographyDisorders of Excessive SomnolenceSettore MED/10 - Malattie Dell'Apparato RespiratorioHypertension risk03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsInternal medicinesystemic arterial hypertensionmedicineHumansEuropean Sleep Apnea DatabaseSleep Apnea ObstructiveSystemic arterial hypertensionbusiness.industrymedicine.diseaseScientific InvestigationsClinical neurologyrespiratory tract diseasesnervous system diseasesObstructive sleep apneamild obstructive sleep apneaDiabetes Mellitus Type 2NeurologyHypertensionNeurology (clinical)Human medicinebusiness030217 neurology & neurosurgery
researchProduct

Comment to the Editorial by KS Park and EW Kang “Is only fixed positive airway pressure a robust tool for kidney protection in patients with obstruct…

2019

We thank doctors Park and Kang for their editorial that well summarized our article. Our common belief is that one of the possible consequences of untreated obstructive sleep apnea (OSA) is an accelerated deterioration of kidney function, and that more knowledge would be necessary on the possible protective effects of OSA treatments. To our knowledge, so far the only OSA therapy whose effects on renal function have been tested is continuous positive airway pressure (CPAP), and most , although not all studies, have demonstrated its benefits. Our own study, while confirming benefits of fixed CPAP, has demonstrated little effect of auto-adjusting CPAP (APAP). This finding may be of relevance a…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyLetterestimated glomerular filtration ratekidney diseaseRenal functionPolysomnographySettore MED/10 - Malattie Dell'Apparato Respiratoriosleep disordered breathingpolysomnographyrenal protectionPositive airway pressureMedicineIn patienthumansleepIntensive care medicinekidney functionLetter to the EditorPositive end-expiratory pressureKidneymedicine.diagnostic_testbusiness.industryobstructive sleep apnea ; kidney protection ; fixed positive airway pressuremedicine.diseaseoxygen saturationrespiratory tract diseasesObstructive sleep apneaNot availablemedicine.anatomical_structureEditorialpositive end expiratory pressureHuman medicinebusinesschronic obstructive lung diseaseKidney disease
researchProduct

Challenges and perspectives in obstructive sleep apnoea: Report by an ad hoc working group of the Sleep Disordered Breathing Group of the European Re…

2018

Obstructive sleep apnoea (OSA) is a major challenge for physicians and healthcare systems throughout the world. The high prevalence and the impact on daily life of OSA oblige clinicians to offer effective and acceptable treatment options. However, recent evidence has raised questions about the benefits of positive airway pressure therapy in ameliorating comorbidities.An international expert group considered the current state of knowledge based on the most relevant publications in the previous 5 years, discussed the current challenges in the field, and proposed topics for future research on epidemiology, phenotyping, underlying mechanisms, prognostic implications and optimal treatment of pat…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyMEDLINEPolysomnographySettore MED/10 - Malattie Dell'Apparato Respiratoriosleepinesslaw.invention03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Randomized controlled trialstomatognathic systemlawPositive airway pressureEpidemiologyMedicineIntensive care medicinesleep apnea: obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseComorbiditynervous system diseasesrespiratory tract diseasesdiagnosi030228 respiratory systemHuman medicinebusiness030217 neurology & neurosurgerysleep apnea phenotyping mechanisms
researchProduct

What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis

2020

Abstract Background The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated factors that may drive general practitioners (GPs) and respiratory specialists in the prescription of inhaler devices for asthma patients who initiated inhalation therapy. Methods We retrospectively analysed prescriptions by GPs and respiratory specialists to asthma patients commencing inhaled corticosteroid/long-acting β2-agonist combination therapy available as both pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). Patient characteristics were compared by device and multivariate analysis was used to model the likelihood of receiving a pMDI as oppos…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyMultivariate analysisSettore MED/10 - Malattie Dell'Apparato RespiratorioGeneral practitioner03 medical and health sciencesdry powder inhaler0302 clinical medicineInhalersAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsAsthma controlGeneral practitionersAdministration InhalationRetrospective analysisMedicine030212 general & internal medicineMetered Dose InhalersMedical prescriptionAsthmaRetrospective Studiesbusiness.industryInhalerdry powder inhalersInhalerOdds ratiomedicine.diseaseConfidence intervalAsthmaPressurised metered-dose inhalerAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialistsPrescriptions030228 respiratory systemRespiratory specialistsInhalationDelayed-Action PreparationsEmergency medicineAdministrationPressurised metered-dose inhalersbusinessAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialists; Administration Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Asthma; Delayed-Action Preparations; Retrospective Studies; Dry Powder Inhalers; Metered Dose Inhalers; Prescriptions
researchProduct

Third-hand smoke exposure and health hazards in children

2013

Smoking still represents a huge public health problem. Millions of children suffer the detrimental effects of passive smoking. An increasing number of countries have recently issued laws to regulate smoking in public places. Instead, homes remain a site where children are dangerously exposed to environmental tobacco smoke (ETS). The combination of tobacco smoke pollutants which remain in an indoor environment, the so-called ‘third-hand smoke’ (THS), represent a new concept in the field of tobacco control. THS consists of pollutants that remain on surfaces and in dust after tobacco has been smoked, are re-emitted into the gas-phase, or react with other compounds in the environment to form se…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPassive smokinglcsh:MedicineSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeTobacco smokeHazardous SubstancesThird-hand smokeSettore MED/38 - Pediatria Generale E SpecialisticaEnvironmental tobacco smokeEnvironmental healthmedicineHumansEnvironmental tobacco smoke Children Lung development Asthma Tobacco control Indoor environment Third-hand smoke.Active smokingThird-hand smokeChildChildrenSmokebusiness.industryPublic healthTobacco controllcsh:RIndoor environmentThird-hand smoke.AsthmaHuman exposureLung developmentTobacco Smoke PollutionTobacco controlCardiology and Cardiovascular Medicinebusiness
researchProduct